Autoplaque vs iPredict Eye Screening
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your clinical practice requires detailed, quantitative analysis of coronary artery plaque and luminal stenoses from CT angiography images. This workstation-based software is ideal for cardiologists and radiologists seeking precise characterization of atherosclerotic disease to guide treatment decisions and refine heart attack risk prediction based on existing CT scans.
View Autoplaque →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if you need a rapid, AI-powered screening solution for multiple ophthalmic conditions, including AMD, DR, and Glaucoma, particularly in primary care or telemedicine settings. This cloud-based platform is excellent for efficient, early detection of eye diseases and provides integrated risk prediction for systemic conditions like stroke and heart attack through retinal imaging.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | iPredict Eye Screening |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B (iPredict Eye Screening) emphasizes ease of operation with an advanced touchscreen interface, fast results (under 5 minutes), and cloud-based accessibility for various settings, including primary care. Tool A (Autoplaque) is workstation-based, suggesting a more specialized and potentially complex workflow for expert users.
Clinical Value
iPredict Eye ScreeningBoth tools offer significant clinical value in their respective domains and are FDA-cleared. However, Tool B (iPredict Eye Screening) provides screening for multiple prevalent conditions (Diabetic Retinopathy, AMD, Glaucoma) and also offers risk prediction for systemic diseases like stroke and heart attack, offering broader clinical utility and population health impact. Tool A focuses on detailed quantitative analysis for coronary plaque, which is highly specialized.
Pricing & Value
iPredict Eye ScreeningTool B (iPredict Eye Screening) provides transparent pricing details, operating on a per-patient SaaS model with an estimated cost range. This allows potential customers to assess the value proposition and budget accordingly. Tool A (Autoplaque) does not disclose its pricing, making it impossible to evaluate its cost-effectiveness.
Enterprise Readiness
iPredict Eye ScreeningTool B (iPredict Eye Screening) is cloud-based, explicitly states HIPAA compliance, and offers EHR integration and telemedicine services, demonstrating strong enterprise readiness and scalability across diverse healthcare environments. Tool A (Autoplaque) is workstation-based and lacks explicit statements regarding HIPAA compliance or Business Associate Agreements (BAA), which are critical for enterprise adoption.
Innovation
iPredict Eye ScreeningWhile Tool A (Autoplaque) offers innovative, highly specialized quantitative analysis of coronary plaque, Tool B (iPredict Eye Screening) presents a broader innovation. It integrates multi-disease screening for prevalent eye conditions with systemic risk prediction for stroke and heart attack, and includes telemedicine integration, offering a more comprehensive and accessible approach to preventative health.
Support & Docs
iPredict Eye ScreeningTool B (iPredict Eye Screening) explicitly mentions '24/7 technical support' and 'training' on its website, indicating a structured and dedicated approach to customer assistance and product education. Tool A (Autoplaque) provides no information regarding support or documentation in the provided facts or through readily available web searches.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | iPredict Eye Screening |
|---|---|---|
| Name | Autoplaque | iPredict Eye Screening |
| Company | Cedars-Sinai Medical Center: AIM | iHealthScreen |
| Primary Focus | AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | AI-powered screening for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), Glaucoma, and risk prediction for systemic diseases like stroke and heart attack. |
| Cardiology-related Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images. | Online Health Risk Prediction System for Heart Attack patients. |
| Other Key Screening/Analysis Areas | Not specified | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector. |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and iPredict Eye Screening.